Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

Dr Sam Maher

 Samuel Maher

Dr Sam Maher BSc (Hons), PhD
Senior Lecturer in Pharmaceutics / School Erasmus Officer
Tel: +353 1 402 2362
Email: sammaher@rcsi.com

Biography
Sam Maher graduated with a PhD from ITT Dublin where he evaluated the toxicological and pharmacological actions of several host defence peptides on in vitro and ex vivo models of the intestinal epithelium. Upon completion of his PhD he carried out research in the UCD Conway Institute on the design of a novel drug eluting stent for the sustained release of an active pharmaceutical ingredient. In 2008 he was awarded an IRCSET post-doctoral grant to carry out research on oral delivery systems for poorly absorbed drugs in the UCD Veterinary Science Centre. He subsequently carried out research in oral formulation of poorly absorbed drugs/functional foods as a member of Food for Health Ireland. In 2011 he was appointed Lecturer in Pharmaceutics in the RCSI School of Pharmacy to cover a staff secondment. He subsequently joined AnaBio Technologies Ltd as an oral formulation product development research scientist. In 2014, he was appointed Lecturer in Pharmaceutics in the RCSI School of Pharmacy.

Research Interests
Development of novel drug delivery systems for poorly absorbed drugs
Oral solid dose formulation (BCS Class II-IV drugs)
Microemulsion based drug delivery systems
Toxicokinetics of pharmaceutical excipients

Publications

PEER REVIEWED PUBLICATIONS

1. Flood S, Hayden JC, Bourke B, Gallagher PJ, Maher S (2017). Design and evaluation of video podcasts for providing online feedback on formative pharmaceutical calculations assessments. American Journal of Pharmaceutical Education (in press).

2. Maher S et al (2017) Development of a non-aqueous dispersion to improve intestinal flux of macromolecules AAPS Journal 19 (1) 244-253.

3. Maher S, Mrsny RD, Brayden DJ (2016). Permeation enhancers for oral peptide delivery. Advanced Drug Delivery Reviews 106B 277-319.

4. Dowling DP, Maher S, et al (2016) Modified drug release using atmospheric pressure plasma deposited siloxane coatings, Journal of Physics D: Applied Physics 49, 36.

5. Brayden DJ, Maher S, Walsh E (2015) Sodium caprate-induced increases in intestinal permeability and epithelial damage are prevented by misoprostol. European Journal of Pharmaceutics and Biopharmaceutics 94:194-206.

6. Maher S, et al (2014). Formulation strategies to improve oral peptide delivery. Pharmaceutical Patent analyst 3 (3): 313-336.

7. Gaudel C, Nongonierma AB, Maher S, et al (2013). Effect of a whey protein hydrolysate on insulin secretion from a clonal pancreatic beta cell line and influence on glycaemic function in ob/ob mice. Journal of Nutrition 143 (7): 1109-14.

8. Petersen SB, Nolan G, Maher S, et al (2012). Evaluation of alkyl maltosides as intestinal permeation enhancers: Comparison between rat intestinal mucosal sheets and Caco-2 monolayers. European Journal of Pharmaceutical Science 47(4):701-12.

9. Mohan HM, Collins D, Maher S, et al (2012). The Mycotoxin Patulin Increases Colonic Epithelial Permeability in vitro. Food and Chemical toxicology (50(11):4097-102).

10. Bahar B, O'Doherty JV, Maher S, et al (2012). Chitooligosaccharide elicits acute inflammatory cytokine response through AP-1 pathway in human intestinal epithelial-like (Caco-2) cells. Molecular Immunology 51, (3-4), 283-291.

11. Maher S, Brayden DJ. (2011). Overcoming poor permeability: Translating permeation enhancers for oral peptide delivery. Drug Discovery Today: Technologies 9 (2) e13-e19.

12. Walsh EG, Maher S, et al (2011). High content screening to determine cytotoxicity of the antimicrobial peptide melittin and selected structural analogues. Peptides 32 (8) 1764-1773

13. Walsh EG, Adamczyk BE, Chalasani KB, Maher S, et al (2011). Oral delivery of macromolecules: rationale underpinning gastrointestinal permeation enhancement technology (GIPET®). Therapeutic Delivery 2, (12) 1595-1610.

14. Wang X, Maher S, et al (2010). Rapid restoration of the colonic epithelium of rats after in situ instillation of the absorption promoter, sodium caprate. Therapeutic Delivery 1 (1) 75-82.

15. Brayden DJ, Maher S, (2010). Oral absorption enhancement-taking the next steps in therapeutic delivery. Therapeutic Delivery 1 (1) 5-9.

16. Maher S, et al (2010). Impact of amino acid replacements on in vitro permeation enhancement and cytotoxicity of the intestinal absorption promoter, melittin. International Journal of Pharmaceutics 387 (1-2) 154-160.

17. Maher S, et al (2009). Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro and in vivo studies. Advanced Drug Delivery Reviews 61 (15) 1427-49.

18. Maher S, et al (2009). Evaluation of intestinal absorption enhancement and local mucosal toxicity of melittin and sodium caprate II: In situ rat instillation and perfusion. European Journal of Pharmaceutical Science 38(4):301-11.

19. Maher S, et al (2009). Evaluation of intestinal absorption enhancement and local mucosal toxicity of melittin and sodium caprate I: Isolated rat and human colonic mucosa. European Journal of Pharmaceutical Science 38(4):291-300.

20. Maher S, et al (2009). Chemical modification of the carboxyl terminal of nisin A with biotin does not abolish antimicrobial activity against indicator organism, Kocuria rhizophila. Peptide Research and therapeutics 15: 219-226.

21. Maher S, et al (2008). Cracking the junction: update on the progress of gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs. Critical reviews in Therapeutic Drug Carrier Systems 25:117-68.

22. Maher S, McClean S, (2008). Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochemical Pharmacology 75:1104-14.

23. Maher S, et al (2007). Melittin as a permeability enhancer II: in vitro investigations in human mucus secreting intestinal monolayers and rat colonic mucosae. Pharmaceutical Research 24:1346-56.

24. Maher S, et al (2007). Melittin as an epithelial permeability enhancer I: investigation of its mechanism of action in Caco-2 monolayers. Pharmaceutical research 24:1336-45.

25. Maher S, McClean S (2006). Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Biochemical Pharmacology 71:1289-98.

BOOK CHAPTERS

26. Maher S, et al (2012). Nanostructures overcoming the intestinal barrier: physiological considerations and mechanistic issues. In Alonso MJ and Csaba NS (Eds) Nanostructured Biomaterials for Overcoming Biological Barriers. Royal Chemical Society 39-62

27. Ryan K, Maher S, et al (2012). Nanostructures overcoming the intestinal barrier: drug delivery strategies. In Alonso MJ and Csaba NS (Eds) Nanostructured Biomaterials for Overcoming Biological Barriers. Royal Chemical Society 63-90

NON PEER REVIEWED RESEARCH DISSEMINATIONS

28. Maher S, Farrell A. (2012). Delivering the Benefits of Functional Foods. Dairy Industries International 77 (2) 19 (invited)

29. Maher S (2017). An Outlook on Oral Peptide Delivery. AAPS Blog (invited)

PUBLISHED ABSTRACTS (PEER REVIEWED)

30. Maher S et al (2016) Development of a non-aqueous dispersion to improve intestinal flux of macromolecules in vitro. Proceedings of the 2016 AAPS Annual Meeting and Exposition of the American Association of Pharmaceutical scientists (Colorado, USA)

31. McCartney F, Waters S, Bleiel S, Brayden DJ, Maher S (2015). Design of a histological score card to standardise the assessment of intestinal toxicity of candidate pharmaceutical excipients. Transactions of the 42nd Annual Meeting & Exposition of the Controlled Release Society (Edinburgh, Scotland).

32. Mohan H, Collins D, Walsh E, Maher S, Edvardsson A, O'Brien P, Brayden D, Baird A, Winter D (2012) The Dietary Mycotoxin Patulin Increases Colonic Epithelial Permeability In Vitro, Irish Journal of Medical Science, 181, (Suppl. 6) S182 (97)

33. Flynn S, Gaudel C, Nongonierma A, Bhate M, Fitzgerald R, Maher S, Baird A, Newsholme P, Brennan L (2012) An investigation into the possible beneficial effects of milk hydrolysates on insulin secretion and metabolic function, Proceedings of the Nutrition Society, 71 E27.

34. Walsh EG, Maher S, Brayden DJ (2012) Misoprostol inhibits in vitro intestinal permeation enhancement effects of the medium chain fatty acid, sodium caprate (C10), Transactions of the 39th Annual Meeting & Exposition of the Controlled Release Society (Quebec, Canada).

35. Maher S, Walsh EG, Devocelle M, O'Brien PJ, Baird AW, Brayden DJ (2011). High content analysis to determine cytotoxicity of the antimicrobial peptide, melittin and selected structural analogs. Transactions of the 13th Annual Congress of the European Society of Veterinary Clinical Pathology (Dublin, Ireland) (Oral, Invited)

36. Maher S, Collins D, Walsh EG, Mohan H, Edvardsson A, Winter D, O'Brien PJ, Baird AW, Brayden DJ (2011). Effect of the mycotoxin patulin on permeability of isolated rat colonic mucosa and high content analysis in Caco-2 cells. Transactions of the 13th Annual Congress of the European Society of Veterinary Clinical Pathology (Dublin, Ireland) (Oral, Invited)

37. Maher S, Brayden DJ (2011). Investigations of Intestinal Epithelial Compensatory Responses to Permeation Enhancement Caused by Sodium Caprate (C10). Transactions of the 38th Annual Meeting and Exposition of the Controlled Release Society (Maryland, USA).

38. Maher S, Wang X, McClean S, Brayden DJ (2008). Increased intestinal permeability induced by the antimicrobial peptide melittin: Ex vivo and in situ studies. Transactions of the 35th Annual Meeting & Exposition of the Controlled Release Society (New York, USA).

39. Maher S, McClean S (2004), Investigation of the cytotoxicity of a series of antimicrobial peptides on intestinal epithelial cells in vitro Journal of Peptide Science, 10, 178-178.

PATENTS

40. Bleiel S, Maher S (2016) Gelated microparticle suitable for oral delivery of therapeutic peptides to the lower intestine. WO 2016178202 A1 

SELECTED OTHER RESEARCH DISSEMINATIONS

Maher S (2016). Commercial Opportunities in Oral Peptide Delivery. AnaBio Technology Ltd, (Dublin, Ireland) (Oral, Invited).

Maher S (2016). A Personal Perspective on How to Harness Research to Build Your Career in Ireland. Inaugural Science Undergraduate Research Conference (DIT-Grangegorman, Dublin, Ireland) (Oral, Invited, Keynote).

Maher S (2016). Current Status in Oral Peptide Delivery (Erasmus Staff Mobility, University Lorraine Nancy, France) (Oral, Invited).

Quinn I, Ramtoola Z, Maher S (2015) Optimisation of a solid dosage form for oral delivery of poorly permeable peptide drugs. RCSI Research Open Day (Dublin, Ireland) (Poster).

Maher S (2010). Intestinal permeation enhancement for poorly absorbed drugs: separating reality from myth 15th International Pharmaceutical Technology Symposium (Antalya, Turkey) (Oral, Invited).

Maher S, (2010). Delivering injectables by the oral route using pharmaceutical excipients. UCD CLASS Conway Lecture & Seminar Series (Dublin, Ireland). (Oral, Invited).

Maher S, McClean S, Brayden DJ (2008). Increased intestinal permeability induced by the antimicrobial peptide, melittin. Predicting drug delivery: opportunities and challenges, Transactions of the 14th United Kingdom and Ireland Controlled Release Society Symposium (London UK) (Oral).

Maher S, McClean S (2005). Investigation of the mechanism of cytotoxicity of a series of AMPs on intestinal epithelial cells in vitro 5th Gordon Research Conference on Antimicrobial Peptides (Los Angeles, USA) (Poster).